| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Perfusion Imaging | 48 | 2023 | 61 | 21.570 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 43 | 2023 | 81 | 13.500 |
Why?
|
| Coronary Artery Disease | 26 | 2023 | 139 | 13.190 |
Why?
|
| Purines | 21 | 2020 | 34 | 9.520 |
Why?
|
| Pyrazoles | 22 | 2020 | 54 | 9.340 |
Why?
|
| Myocardial Ischemia | 14 | 2020 | 49 | 6.560 |
Why?
|
| Kidney Failure, Chronic | 12 | 2023 | 161 | 5.760 |
Why?
|
| Exercise Test | 23 | 2020 | 129 | 5.160 |
Why?
|
| Myocardial Infarction | 14 | 2023 | 178 | 5.000 |
Why?
|
| Thrombosis | 10 | 2022 | 64 | 4.570 |
Why?
|
| Kidney Transplantation | 7 | 2023 | 126 | 4.250 |
Why?
|
| Adenosine A2 Receptor Agonists | 10 | 2019 | 11 | 4.020 |
Why?
|
| Prognosis | 34 | 2023 | 924 | 3.860 |
Why?
|
| Atrial Fibrillation | 13 | 2022 | 223 | 3.630 |
Why?
|
| Aminophylline | 9 | 2018 | 9 | 3.230 |
Why?
|
| Heart Failure | 14 | 2022 | 223 | 3.110 |
Why?
|
| Humans | 132 | 2023 | 31073 | 3.020 |
Why?
|
| Middle Aged | 61 | 2022 | 10240 | 2.750 |
Why?
|
| Heart Diseases | 5 | 2021 | 77 | 2.640 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2021 | 101 | 2.630 |
Why?
|
| Male | 74 | 2023 | 16499 | 2.560 |
Why?
|
| Risk Assessment | 22 | 2021 | 718 | 2.530 |
Why?
|
| Female | 75 | 2023 | 17017 | 2.480 |
Why?
|
| Risk Factors | 34 | 2023 | 2591 | 2.210 |
Why?
|
| Liver Transplantation | 4 | 2021 | 80 | 2.210 |
Why?
|
| Echocardiography, Transesophageal | 6 | 2019 | 49 | 2.180 |
Why?
|
| Atrial Appendage | 8 | 2022 | 57 | 2.170 |
Why?
|
| Patient Selection | 7 | 2021 | 246 | 2.160 |
Why?
|
| Cardiology | 9 | 2020 | 75 | 2.040 |
Why?
|
| Retrospective Studies | 32 | 2023 | 3665 | 2.020 |
Why?
|
| Aged | 48 | 2022 | 10082 | 1.980 |
Why?
|
| Vasodilator Agents | 9 | 2018 | 33 | 1.970 |
Why?
|
| Heart | 7 | 2023 | 99 | 1.900 |
Why?
|
| Stroke Volume | 9 | 2022 | 70 | 1.870 |
Why?
|
| Predictive Value of Tests | 17 | 2021 | 555 | 1.780 |
Why?
|
| Electrocardiography | 6 | 2018 | 225 | 1.760 |
Why?
|
| Coronary Angiography | 8 | 2023 | 99 | 1.700 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2015 | 20 | 1.660 |
Why?
|
| Pulmonary Embolism | 5 | 2022 | 64 | 1.560 |
Why?
|
| Heart Rate | 3 | 2017 | 160 | 1.550 |
Why?
|
| Echocardiography | 9 | 2023 | 179 | 1.530 |
Why?
|
| Reproducibility of Results | 15 | 2019 | 820 | 1.510 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2021 | 12 | 1.460 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 90 | 1.440 |
Why?
|
| Prospective Studies | 19 | 2020 | 1899 | 1.410 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2022 | 24 | 1.290 |
Why?
|
| Mitral Valve | 3 | 2020 | 12 | 1.290 |
Why?
|
| Sensitivity and Specificity | 12 | 2018 | 586 | 1.240 |
Why?
|
| Nuclear Medicine | 5 | 2019 | 6 | 1.210 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2022 | 47 | 1.180 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2022 | 360 | 1.160 |
Why?
|
| Cardiovascular Diseases | 6 | 2021 | 428 | 1.150 |
Why?
|
| Drug-Eluting Stents | 3 | 2022 | 11 | 1.140 |
Why?
|
| Unnecessary Procedures | 3 | 2015 | 28 | 1.110 |
Why?
|
| Troponin I | 2 | 2017 | 13 | 1.100 |
Why?
|
| Heart-Assist Devices | 4 | 2019 | 24 | 1.100 |
Why?
|
| Coronary Stenosis | 2 | 2018 | 14 | 1.100 |
Why?
|
| Transcatheter Aortic Valve Replacement | 6 | 2023 | 34 | 1.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 26 | 1.080 |
Why?
|
| Multimodal Imaging | 3 | 2021 | 22 | 1.070 |
Why?
|
| Ventricular Function, Left | 5 | 2020 | 55 | 1.040 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2021 | 13 | 1.020 |
Why?
|
| United States | 17 | 2023 | 2376 | 1.000 |
Why?
|
| Treatment Outcome | 27 | 2023 | 3810 | 1.000 |
Why?
|
| Conservative Treatment | 2 | 2021 | 14 | 0.940 |
Why?
|
| Comorbidity | 9 | 2021 | 508 | 0.940 |
Why?
|
| Heart Valve Diseases | 3 | 2020 | 27 | 0.940 |
Why?
|
| Biomarkers | 8 | 2021 | 734 | 0.940 |
Why?
|
| Angina Pectoris | 2 | 2023 | 20 | 0.930 |
Why?
|
| Diarrhea | 3 | 2012 | 48 | 0.920 |
Why?
|
| Heart Ventricles | 3 | 2021 | 183 | 0.910 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 30 | 0.900 |
Why?
|
| Incidence | 9 | 2020 | 790 | 0.890 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2023 | 10 | 0.880 |
Why?
|
| Chicago | 10 | 2019 | 941 | 0.860 |
Why?
|
| Insurance Coverage | 2 | 2020 | 16 | 0.830 |
Why?
|
| Medicaid | 2 | 2020 | 39 | 0.810 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2022 | 54 | 0.800 |
Why?
|
| Medicare | 2 | 2019 | 127 | 0.770 |
Why?
|
| Calcium | 3 | 2021 | 503 | 0.760 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 1935 | 0.760 |
Why?
|
| Hematoma | 1 | 2021 | 21 | 0.760 |
Why?
|
| Cardiomyopathies | 3 | 2020 | 37 | 0.750 |
Why?
|
| Coronary Vessels | 1 | 2021 | 47 | 0.750 |
Why?
|
| Double-Blind Method | 7 | 2016 | 499 | 0.750 |
Why?
|
| Image Enhancement | 2 | 2018 | 60 | 0.740 |
Why?
|
| Cohort Studies | 10 | 2020 | 2046 | 0.740 |
Why?
|
| Adult | 15 | 2020 | 8950 | 0.730 |
Why?
|
| Survival Rate | 6 | 2017 | 407 | 0.730 |
Why?
|
| Antihypertensive Agents | 2 | 2022 | 88 | 0.720 |
Why?
|
| Atrioventricular Node | 1 | 2020 | 6 | 0.720 |
Why?
|
| Diltiazem | 1 | 2020 | 7 | 0.720 |
Why?
|
| Primary Health Care | 2 | 2013 | 100 | 0.720 |
Why?
|
| Hyperkalemia | 1 | 2020 | 7 | 0.720 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1134 | 0.710 |
Why?
|
| Bradycardia | 1 | 2020 | 33 | 0.710 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 22 | 0.700 |
Why?
|
| Critical Pathways | 2 | 2017 | 22 | 0.700 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 10 | 0.690 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2019 | 2 | 0.690 |
Why?
|
| Tissue Survival | 1 | 2019 | 1 | 0.680 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 34 | 0.680 |
Why?
|
| Multidetector Computed Tomography | 2 | 2021 | 9 | 0.680 |
Why?
|
| Calcinosis | 1 | 2020 | 50 | 0.680 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 16 | 0.670 |
Why?
|
| Syncope | 1 | 2019 | 8 | 0.670 |
Why?
|
| Bundle-Branch Block | 1 | 2019 | 18 | 0.660 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2019 | 2 | 0.650 |
Why?
|
| Echocardiography, Doppler | 2 | 2016 | 23 | 0.650 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 52 | 0.650 |
Why?
|
| Cardiac Tamponade | 1 | 2018 | 3 | 0.640 |
Why?
|
| Oximetry | 1 | 2018 | 12 | 0.640 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 5197 | 0.640 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 167 | 0.640 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 33 | 0.630 |
Why?
|
| Machine Learning | 1 | 2019 | 63 | 0.630 |
Why?
|
| Pericardial Effusion | 1 | 2018 | 4 | 0.620 |
Why?
|
| Myocardium | 2 | 2019 | 147 | 0.620 |
Why?
|
| Aortic Valve | 5 | 2023 | 28 | 0.610 |
Why?
|
| Contrast Media | 1 | 2018 | 136 | 0.600 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2017 | 5 | 0.570 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2017 | 1 | 0.570 |
Why?
|
| Medical Overuse | 1 | 2017 | 7 | 0.570 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 60 | 0.570 |
Why?
|
| Preoperative Care | 2 | 2015 | 144 | 0.570 |
Why?
|
| Accreditation | 1 | 2016 | 17 | 0.560 |
Why?
|
| Purinergic P1 Receptor Antagonists | 2 | 2013 | 2 | 0.540 |
Why?
|
| Hospitalization | 6 | 2021 | 336 | 0.540 |
Why?
|
| Prevalence | 7 | 2023 | 499 | 0.540 |
Why?
|
| Hemodynamics | 1 | 2016 | 89 | 0.530 |
Why?
|
| Radiation Exposure | 1 | 2016 | 12 | 0.530 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 16 | 0.530 |
Why?
|
| Guideline Adherence | 4 | 2019 | 68 | 0.530 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2016 | 11 | 0.530 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 1 | 0.530 |
Why?
|
| Sexism | 1 | 2015 | 7 | 0.510 |
Why?
|
| Hospital Mortality | 5 | 2021 | 150 | 0.510 |
Why?
|
| Registries | 4 | 2023 | 203 | 0.510 |
Why?
|
| Insurance Carriers | 1 | 2015 | 3 | 0.510 |
Why?
|
| Adenosine | 1 | 2015 | 12 | 0.510 |
Why?
|
| Technetium | 1 | 2015 | 6 | 0.500 |
Why?
|
| Cardiotonic Agents | 4 | 2018 | 14 | 0.500 |
Why?
|
| Perfusion | 4 | 2023 | 22 | 0.490 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 12 | 0.490 |
Why?
|
| Social Class | 1 | 2015 | 69 | 0.490 |
Why?
|
| Physicians' Offices | 2 | 2013 | 7 | 0.480 |
Why?
|
| Myocardial Revascularization | 4 | 2020 | 18 | 0.480 |
Why?
|
| Rheumatic Heart Disease | 1 | 2014 | 2 | 0.470 |
Why?
|
| Hyperemia | 1 | 2014 | 2 | 0.470 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 1 | 0.460 |
Why?
|
| Thrombophilia | 1 | 2014 | 7 | 0.460 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 20 | 0.460 |
Why?
|
| Hyperthyroidism | 1 | 2014 | 13 | 0.460 |
Why?
|
| Thromboembolism | 1 | 2014 | 20 | 0.460 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 1006 | 0.450 |
Why?
|
| Heart Failure, Systolic | 1 | 2013 | 5 | 0.450 |
Why?
|
| Technetium Tc 99m Sestamibi | 3 | 2019 | 9 | 0.440 |
Why?
|
| Women's Health | 1 | 2015 | 242 | 0.440 |
Why?
|
| Renal Dialysis | 3 | 2019 | 111 | 0.430 |
Why?
|
| Urban Population | 1 | 2014 | 148 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 190 | 0.430 |
Why?
|
| Diabetes Complications | 1 | 2013 | 68 | 0.430 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 53 | 0.430 |
Why?
|
| Lung | 1 | 2014 | 173 | 0.420 |
Why?
|
| Dizziness | 1 | 2012 | 20 | 0.420 |
Why?
|
| Physicians | 1 | 2014 | 119 | 0.410 |
Why?
|
| Angina, Unstable | 2 | 2002 | 11 | 0.410 |
Why?
|
| Abdominal Pain | 1 | 2012 | 10 | 0.410 |
Why?
|
| Algorithms | 3 | 2019 | 416 | 0.400 |
Why?
|
| Odds Ratio | 4 | 2018 | 293 | 0.390 |
Why?
|
| Sex Distribution | 3 | 2016 | 90 | 0.390 |
Why?
|
| Exercise | 1 | 2016 | 505 | 0.380 |
Why?
|
| Time Factors | 6 | 2019 | 1680 | 0.370 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 149 | 0.370 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 344 | 0.370 |
Why?
|
| Patient Positioning | 1 | 2011 | 41 | 0.370 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 42 | 0.370 |
Why?
|
| Observational Studies as Topic | 3 | 2019 | 22 | 0.360 |
Why?
|
| Positron-Emission Tomography | 4 | 2019 | 98 | 0.350 |
Why?
|
| Ambulatory Care | 1 | 2010 | 79 | 0.350 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 35 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 5 | 2017 | 344 | 0.340 |
Why?
|
| Utilization Review | 3 | 2020 | 7 | 0.340 |
Why?
|
| Thallium Radioisotopes | 2 | 2019 | 6 | 0.330 |
Why?
|
| Troponin | 3 | 2021 | 8 | 0.300 |
Why?
|
| Acute Disease | 3 | 2021 | 232 | 0.300 |
Why?
|
| Radionuclide Imaging | 2 | 2020 | 55 | 0.300 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 61 | 0.300 |
Why?
|
| Stroke | 3 | 2022 | 315 | 0.290 |
Why?
|
| Risk | 3 | 2020 | 223 | 0.290 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 225 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 225 | 0.270 |
Why?
|
| Benchmarking | 2 | 2023 | 46 | 0.260 |
Why?
|
| Feasibility Studies | 5 | 2022 | 244 | 0.260 |
Why?
|
| Causality | 2 | 2016 | 54 | 0.260 |
Why?
|
| Age Distribution | 2 | 2016 | 96 | 0.260 |
Why?
|
| Chronic Disease | 3 | 2019 | 534 | 0.260 |
Why?
|
| Propensity Score | 2 | 2016 | 36 | 0.260 |
Why?
|
| Logistic Models | 2 | 2018 | 411 | 0.250 |
Why?
|
| ROC Curve | 2 | 2016 | 145 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 370 | 0.250 |
Why?
|
| Illinois | 3 | 2021 | 267 | 0.250 |
Why?
|
| Administration, Intravenous | 2 | 2016 | 28 | 0.250 |
Why?
|
| Patient Compliance | 2 | 2017 | 158 | 0.250 |
Why?
|
| Syndrome | 2 | 2023 | 83 | 0.230 |
Why?
|
| Decision Making | 2 | 2017 | 236 | 0.230 |
Why?
|
| Point-of-Care Systems | 2 | 2018 | 63 | 0.230 |
Why?
|
| Cause of Death | 2 | 2015 | 70 | 0.230 |
Why?
|
| Dyspnea | 1 | 2023 | 44 | 0.210 |
Why?
|
| Placebo Effect | 2 | 2014 | 24 | 0.210 |
Why?
|
| Hypotension | 1 | 2022 | 32 | 0.210 |
Why?
|
| Anticoagulants | 3 | 2022 | 110 | 0.210 |
Why?
|
| Pericardium | 2 | 2021 | 21 | 0.210 |
Why?
|
| Journal Impact Factor | 2 | 2020 | 17 | 0.210 |
Why?
|
| Pilot Projects | 3 | 2014 | 428 | 0.200 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 32 | 0.200 |
Why?
|
| Pulmonary Veins | 1 | 2022 | 40 | 0.200 |
Why?
|
| Ultrasonography | 2 | 2014 | 271 | 0.200 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 11 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2019 | 164 | 0.190 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2020 | 1 | 0.180 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adipose Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
| Ischemia | 1 | 2020 | 28 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2020 | 24 | 0.180 |
Why?
|
| Electric Countershock | 1 | 2020 | 29 | 0.180 |
Why?
|
| Inpatients | 2 | 2019 | 150 | 0.170 |
Why?
|
| Sample Size | 1 | 2019 | 25 | 0.170 |
Why?
|
| Prospective Payment System | 1 | 2019 | 4 | 0.170 |
Why?
|
| Ventriculography, First-Pass | 1 | 2019 | 1 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2021 | 144 | 0.170 |
Why?
|
| Health Resources | 1 | 2019 | 24 | 0.170 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 7 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 31 | 0.170 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 3 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 17 | 0.170 |
Why?
|
| Publication Bias | 1 | 2019 | 8 | 0.170 |
Why?
|
| Electrodes, Implanted | 1 | 2019 | 48 | 0.170 |
Why?
|
| Medication Adherence | 2 | 2020 | 73 | 0.170 |
Why?
|
| Models, Statistical | 1 | 2019 | 135 | 0.160 |
Why?
|
| Writing | 1 | 2019 | 22 | 0.160 |
Why?
|
| Angioplasty, Balloon | 1 | 2019 | 19 | 0.160 |
Why?
|
| Outpatients | 1 | 2019 | 57 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 29 | 0.160 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 46 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 76 | 0.160 |
Why?
|
| Antidotes | 1 | 2018 | 6 | 0.160 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 17 | 0.160 |
Why?
|
| Coronary Circulation | 1 | 2018 | 43 | 0.160 |
Why?
|
| Pericardial Window Techniques | 1 | 2018 | 3 | 0.160 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 3 | 0.160 |
Why?
|
| Plethysmography | 1 | 2018 | 4 | 0.160 |
Why?
|
| Sphygmomanometers | 1 | 2018 | 3 | 0.160 |
Why?
|
| Vasodilation | 1 | 2018 | 19 | 0.160 |
Why?
|
| Death | 2 | 2022 | 53 | 0.160 |
Why?
|
| Kidney | 1 | 2020 | 181 | 0.160 |
Why?
|
| Young Adult | 2 | 2016 | 2061 | 0.160 |
Why?
|
| Heart Atria | 1 | 2019 | 73 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 71 | 0.160 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2013 | 49 | 0.160 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2019 | 92 | 0.160 |
Why?
|
| Respiration | 1 | 2018 | 35 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2018 | 4 | 0.160 |
Why?
|
| Hospice Care | 1 | 2019 | 33 | 0.160 |
Why?
|
| Hospitals | 1 | 2019 | 165 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 216 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2018 | 12 | 0.150 |
Why?
|
| Tachycardia | 1 | 2018 | 53 | 0.150 |
Why?
|
| Research Design | 1 | 2019 | 219 | 0.150 |
Why?
|
| Potassium | 1 | 2018 | 68 | 0.150 |
Why?
|
| Angina, Stable | 1 | 2017 | 2 | 0.150 |
Why?
|
| Veterans | 1 | 2019 | 70 | 0.150 |
Why?
|
| Chest Pain | 1 | 2017 | 24 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2019 | 132 | 0.150 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 24 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 42 | 0.150 |
Why?
|
| Central Venous Pressure | 1 | 2017 | 5 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 154 | 0.140 |
Why?
|
| Arterial Pressure | 1 | 2017 | 15 | 0.140 |
Why?
|
| Patient Safety | 1 | 2017 | 53 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2015 | 301 | 0.140 |
Why?
|
| Organophosphorus Compounds | 1 | 2016 | 4 | 0.140 |
Why?
|
| Perfusion Imaging | 1 | 2016 | 5 | 0.140 |
Why?
|
| Organotechnetium Compounds | 1 | 2016 | 7 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.140 |
Why?
|
| Radiation Protection | 1 | 2016 | 5 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2020 | 227 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2016 | 70 | 0.130 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 6 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2016 | 23 | 0.130 |
Why?
|
| Heart Rate Determination | 1 | 2015 | 1 | 0.130 |
Why?
|
| Sympathetic Nervous System | 1 | 2015 | 9 | 0.130 |
Why?
|
| Sex Factors | 2 | 2016 | 510 | 0.130 |
Why?
|
| Workload | 1 | 2015 | 34 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2015 | 120 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 39 | 0.130 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 9 | 0.130 |
Why?
|
| Rest | 1 | 2015 | 31 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 875 | 0.120 |
Why?
|
| Health Services Misuse | 1 | 2015 | 3 | 0.120 |
Why?
|
| Self Care | 1 | 2016 | 91 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 4 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 231 | 0.120 |
Why?
|
| Remote Consultation | 1 | 2014 | 12 | 0.120 |
Why?
|
| Population Groups | 1 | 2014 | 6 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 60 | 0.120 |
Why?
|
| Robotics | 1 | 2014 | 14 | 0.120 |
Why?
|
| Surgeons | 1 | 2015 | 87 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 149 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 135 | 0.110 |
Why?
|
| Dilatation | 1 | 2013 | 9 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 208 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 79 | 0.110 |
Why?
|
| Network Meta-Analysis | 2 | 2022 | 28 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 31 | 0.100 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 1 | 0.100 |
Why?
|
| Premedication | 1 | 2012 | 4 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 57 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2012 | 62 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 409 | 0.100 |
Why?
|
| Asthma | 1 | 2014 | 143 | 0.100 |
Why?
|
| Supine Position | 1 | 2011 | 17 | 0.090 |
Why?
|
| Safety | 1 | 2010 | 50 | 0.090 |
Why?
|
| Diastole | 1 | 2010 | 36 | 0.090 |
Why?
|
| Child | 1 | 2014 | 1431 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2022 | 81 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2022 | 139 | 0.080 |
Why?
|
| Internet | 2 | 2020 | 92 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 453 | 0.080 |
Why?
|
| Aging | 1 | 2018 | 1729 | 0.080 |
Why?
|
| Adolescent | 1 | 2014 | 2403 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 214 | 0.070 |
Why?
|
| Equipment Design | 2 | 2019 | 189 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1318 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 3 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2023 | 53 | 0.050 |
Why?
|
| Neprilysin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 10 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 41 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 28 | 0.050 |
Why?
|
| Lasers | 1 | 2022 | 21 | 0.050 |
Why?
|
| Hematologic Agents | 1 | 2002 | 3 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 10 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 246 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 63 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2021 | 98 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 43 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2019 | 1 | 0.040 |
Why?
|
| Bias | 1 | 2019 | 36 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 45 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2019 | 100 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2019 | 9 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Authorship | 1 | 2019 | 16 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2019 | 28 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 47 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 30 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 69 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 32 | 0.040 |
Why?
|
| Checklist | 1 | 2019 | 38 | 0.040 |
Why?
|
| Bibliometrics | 1 | 2019 | 28 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 32 | 0.040 |
Why?
|
| Veterans Health | 1 | 2018 | 1 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 7 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 20 | 0.040 |
Why?
|
| Software | 1 | 2018 | 73 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 328 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 354 | 0.040 |
Why?
|
| Research Report | 1 | 2017 | 7 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 339 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2016 | 8 | 0.040 |
Why?
|
| Dabigatran | 1 | 2016 | 7 | 0.040 |
Why?
|
| Pyridones | 1 | 2016 | 13 | 0.040 |
Why?
|
| Thiazoles | 1 | 2016 | 31 | 0.030 |
Why?
|
| Pyridines | 1 | 2016 | 47 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 89 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 39 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 334 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 33 | 0.030 |
Why?
|
| Current Procedural Terminology | 1 | 2015 | 14 | 0.030 |
Why?
|
| MEDLINE | 1 | 2015 | 5 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 177 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 9 | 0.030 |
Why?
|
| Learning Curve | 1 | 2014 | 19 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 818 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2014 | 41 | 0.030 |
Why?
|
| Materials Testing | 1 | 2014 | 135 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1507 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 997 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2014 | 241 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 44 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 288 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 370 | 0.020 |
Why?
|